Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
Primary Purpose
Morbid Obesity
Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Endolumik Gastric Calibration Tube (EGCT)
Sponsored by
About this trial
This is an interventional treatment trial for Morbid Obesity
Eligibility Criteria
Inclusion Criteria:
- English speaking
- Adults (between age of 18 and 65 years old)
- Have body mass index (BMI) between 35 and 65.99 kg/m2
- Male or female bariatric patients undergoing bariatric surgery at one of the two sites included in the protocol.
Exclusion Criteria:
- Nonbariatric patients
- Patients who have conditions that preclude a sleeve gastrectomy or gastric bypass operation
- Patients with esophageal stricture
- Patients with esophageal varices
- Patients with a Zenker's diverticulum
- Patients aged 66 and older
- Patients with a BMI of 66 kg/m2 or greater
- Pregnant Women
- Lactating Women
- Other vulnerable patient populations: pregnant and lactating women, prisoners, cognitively impaired and critically ill subjects.
Sites / Locations
- West Virginia University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Bariatric Surgery
Arm Description
Up to twenty participants meeting inclusion criteria will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube. Up to ten participants meeting inclusion criteria will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
Outcomes
Primary Outcome Measures
Intraoperative adverse events
Adverse events occurring during surgical treatment
Operative time
Duration of surgical treatment
30-day morbidity
any 30-day Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Occurrences
Secondary Outcome Measures
Full Information
NCT ID
NCT05486325
First Posted
August 1, 2022
Last Updated
August 1, 2022
Sponsor
Endolumik, Inc
Collaborators
West Virginia University
1. Study Identification
Unique Protocol Identification Number
NCT05486325
Brief Title
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
Official Title
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Endolumik, Inc
Collaborators
West Virginia University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs. During this clinical study, the single-use, disposable Endolumik Gastric Calibration Tube will be used during twenty sleeve gastrectomy operations and gastric bypass operations.
Detailed Description
Endolumik Inc. has developed a fluorescence-guided calibration device, the Endolumik Gastric Calibration Tube, to improve visualization during bariatric operations. The present pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs. During this clinical study, the single-use, disposable Endolumik Gastric Calibration Tube will be used during twenty sleeve gastrectomy operations and gastric bypass operations. The goal of the present study is to confirm that the Endolumik Gastric Calibration Tube performs similar to predicate devices currently on the market, as well as to get end-user feedback prior to submitting a 510(k) application to the U.S. Food and Drug Administration (FDA).
In this multicenter trial, both study sites are certified as Bariatric Centers of Excellence through the American Society of Metabolic and Bariatric Surgery. The first clinical site is Ruby Memorial Hospital, part of West Virginia University; the second clinical site is Durham Regional Hospital, part of Duke University.
To date, using funding from a West Virginia Clinical & Translational Science Institute Launch Pilot Grant, our team has validated the device and associated methods of fluorescence-guided sleeve gastrectomy and fluorescence-guided gastric bypass in ex-vivo and in-vivo porcine models, as well as human cadaveric tissue models. Based on FDA criteria, this investigational device meets the definition of a Non-Significant Risk (NSR) device; the risk classification document is included with submission materials.
The investigational device provided will have met design controls per FDA code of federal regulation (CFR): 21 CFR 820.30. Endolumik Inc. will serve as the industry sponsor for this study and will donate the devices being used for the protocol to the two participating study sites. Development of the technology in this research is supported by the West Virginia University Department of Surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
The sample size (n) will be 20-30 Bariatric patients. Twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube.
Ten participants will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
The current pilot protocol is a qualitative, not quantitative, study design, thus no power calculation is indicated. The goal of the present pilot study is to serve as the First In Human trial and confirm that the Endolumik Gastric Calibration Tube performs similar to predicate devices currently on the market, as well as to get end-user feedback prior to 510(k) application to the FDA. The sample size was chosen because 20 to 30 uses will allow the development team to appropriately evaluate device performance.
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Bariatric Surgery
Arm Type
Experimental
Arm Description
Up to twenty participants meeting inclusion criteria will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube. Up to ten participants meeting inclusion criteria will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
Intervention Type
Device
Intervention Name(s)
Endolumik Gastric Calibration Tube (EGCT)
Intervention Description
Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.
The portions of the sleeve gastrectomy operation where the EGCT will be used include:
To evacuate gastric contents
During construction of the gastric sleeve
To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.
The portions of the gastric bypass operation where the EGCT will be used include:
To evacuate gastric contents
During construction of the gastric pouch
To calibrate closure of the gastrojejunal anastomosis
To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia.
Primary Outcome Measure Information:
Title
Intraoperative adverse events
Description
Adverse events occurring during surgical treatment
Time Frame
During surgical treatment
Title
Operative time
Description
Duration of surgical treatment
Time Frame
During surgical treatment
Title
30-day morbidity
Description
any 30-day Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Occurrences
Time Frame
30 days post surgical treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
English speaking
Adults (between age of 18 and 65 years old)
Have body mass index (BMI) between 35 and 65.99 kg/m2
Male or female bariatric patients undergoing bariatric surgery at one of the two sites included in the protocol.
Exclusion Criteria:
Nonbariatric patients
Patients who have conditions that preclude a sleeve gastrectomy or gastric bypass operation
Patients with esophageal stricture
Patients with esophageal varices
Patients with a Zenker's diverticulum
Patients aged 66 and older
Patients with a BMI of 66 kg/m2 or greater
Pregnant Women
Lactating Women
Other vulnerable patient populations: pregnant and lactating women, prisoners, cognitively impaired and critically ill subjects.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mara McFadden
Phone
5104684426
Email
mcfadden@endolumik.com
First Name & Middle Initial & Last Name or Official Title & Degree
Nova Szoka, Dr.
Phone
13049067613
Email
szoka@endolumik.com
Facility Information:
Facility Name
West Virginia University
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26505
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Schneller
Phone
304-293-3993
Email
wvusponsoredprograms@mail.wvu.edu
First Name & Middle Initial & Last Name & Degree
Lawrence Tabone, Dr.
Phone
3042931728
Email
letabone@hsc.wvu.edu
First Name & Middle Initial & Last Name & Degree
Lawrence Tabone, Dr.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29370995
Citation
English WJ, DeMaria EJ, Brethauer SA, Mattar SG, Rosenthal RJ, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis. 2018 Mar;14(3):259-263. doi: 10.1016/j.soard.2017.12.013. Epub 2017 Dec 16.
Results Reference
background
PubMed Identifier
27129804
Citation
Mahawar KK. Bougie-Related Oesophageal Injury with Bariatric Surgery: An Unrecognised Problem. Obes Surg. 2016 Aug;26(8):1935-6. doi: 10.1007/s11695-016-2213-1. No abstract available.
Results Reference
background
PubMed Identifier
31924187
Citation
Lovece A, Rouvelas I, Hayami M, Lindblad M, Tsekrekos A. Cervical esophageal perforation caused by the use of bougie during laparoscopic sleeve gastrectomy: a case report and review of the literature. BMC Surg. 2020 Jan 10;20(1):9. doi: 10.1186/s12893-020-0679-1.
Results Reference
background
Links:
URL
https://www.cdc.gov/obesity/data/adult.html
Description
Morbid Obesity Data
URL
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Description
Morbid Obesity Data
URL
https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers
Description
Bariatric Surgery Data
URL
https://pubmed.ncbi.nlm.nih.gov/?term=fluorescence+guided+and+surgery+or+indocyanine+green+and+surgery
Description
Fluorescence Guided Surgery
Learn more about this trial
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
We'll reach out to this number within 24 hrs